Achiko Logo cropped.jpg
Achiko AG Announces Corporate Update Webcast
16 nov. 2022 10h38 HE | Achiko AG
ZURICH, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”), a healthcare technology company that is developing new...
Achiko Logo cropped.jpg
Achiko AG Commences Commercial Deliveries in Indonesia
14 nov. 2022 07h30 HE | Achiko AG
ZURICH, Switzerland, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”) is proud to...
Achiko Logo cropped.jpg
Achiko AG Production and Company Update
02 nov. 2022 07h34 HE | Achiko AG
Completing Production Pilot for Generation 2 of AptameX™ as a Precursor to Mass Commercial ProductionExpect to Commence Delivery to Sales and Marketing Contract with Nahdlatul Ulama on Commencement of...
Dyadic Logo Current.jpg
Dyadic Receives Regulatory Approval to Initiate Phase 1 Clinical Trial to Demonstrate Clinical Safety and Efficacy in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
27 oct. 2022 09h04 HE | Dyadic International, Inc.
JUPITER, Fla., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
Pfizer und BioNTech
Pfizer und BioNTech erhalten positive CHMP-Empfehlung für COMIRNATY® für Kinder im Alter von 6 Monaten bis unter 5 Jahren in der Europäischen Union
19 oct. 2022 11h45 HE | BioNTech SE
NEW YORK und MAINZ, Deutschland, 19. Oktober 2022 — Pfizer Inc. (NYSE: PFE, „Pfizer“) und BioNTech SE (Nasdaq: BNTX, „BioNTech“) gaben heute bekannt, dass der Ausschuss für Humanarzneimittel...
Pfizer and BioNTech
Pfizer and BioNTech Receive Positive CHMP Opinion for COMIRNATY® in Children 6 Months to less than 5 Years in the European Union
19 oct. 2022 11h45 HE | BioNTech SE
NEW YORK and MAINZ, Germany, October 19, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for...
Achiko Logo cropped.jpg
Achiko AG Appoints New Chief Financial Officer
07 oct. 2022 07h30 HE | Achiko AG
ZURICH, Switzerland, Oct. 07, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”), a healthcare...
Dyadic Logo Current.jpg
Dyadic to Present Disruptive C1 Technology at World Vaccine Congress Europe Announcing Expansion of Influenza Pipeline with Enhanced Efficacy Potential
04 oct. 2022 08h45 HE | Dyadic International, Inc.
JUPITER, Fla., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Achiko Logo cropped.jpg
Achiko AG Reports First Half to June 30, 2022 Results and Provides Corporate Update as of September 30, 2022
03 oct. 2022 07h33 HE | Achiko AG
Achiko reports an EBITDA loss of USD $1.9 million, compared to an EBITDA loss of USD $4.6 million for the six months ending June 30, 2021.Focal points of the first half year were completion of a major...
Dyadic Logo Current.jpg
Dyadic Updates Market on Recent Scientific Achievements
13 sept. 2022 08h00 HE | Dyadic International, Inc.
JUPITER, Fla., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...